Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone) [ID503]: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Evaluation report:
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer - Janssen
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission - Prostate Cancer UK
06 - Consultee submission - Tackle Prostate Cance
07 - Consultee submission - BAUS
08 - Consultee submission - British Uro-oncology Group
09 - Consultee submission - NCRI-RCP-RCR-ACP-JCCO
10 - Expert personal perspective from Dr John Graham
11 - Expert personal perspective from Dr Simon Hughes
12 - Expert personal perspective from David Smith
13 - Expert personal perspective from Stuart Watson
14 - Evidence Review Group report prepared by Kleijnen Systematic Reviews
15 - Erratum to Evidence Review Group report prepared by Kleijnen Systematic Reviews
16 - Manufacturer factual accuracy check of Evidence Review Group report
Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone) [ID503]: evaluation report
13 May 2014 (6.1 Mb 20 sec) |
This page was last updated: 09 May 2014